P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

December 2008

Features

Interpreting Estimates of Treatment Effects

Health care professionals must consider drug-related adverse events along with efficacy when they prescribe medications. In explaining such concepts as statistical significance and magnitude of effect, the author suggests how indirect comparisons of studies can be used to help guide treatment decisions, especially if patients are taking other agents and combination therapy.
Stephen V. Faraone, PhD

Meeting Highlights

Chemotherapy Foundation Symposium XXVI

Presentations included voreloxin for acute myelogenous leukemia; azacytidine (Vidaza) and decitabine (Depo-Cyt) for myelodysplastic syndromes; lenalidomide (Revlimid) for lymphoma; and dasatinib (Sprycel), nilotinib (Tasigna), and other investigational agents for chronic myelogenous leukemia.
Marvin M. Goldenberg, PhD, RPh, MS

Meeting Highlights

Fourth Annual Ophthalmic Drug Development and Delivery Summit
Third Annual Onmark National Payor/Provider Forum

Topics discussed at the ophthalmic meeting included medications for dry eye and for diabetes-related conditions. The Onmark Forum focused on the anticipated need for collaboration between oncologists and adjunctive personnel because of a workforce gap; online information gathering; and standardizing procedures.
Walter Alexander

Continuing Education Credit

Classification and Pharmacological Management of Obesity

Obesity can have deleterious effects on health, often leading to diabetes and ­cardiovascular disease. Bariatric surgery, diet and behavior modification, and ­current and investigational drug therapies are some of the tools that are available now to help the overweight patient population.
Sarah R. Erlanger, PharmD, and Emily A. Henson, PharmD

Season’s Greetings: Thanks to Our Readers and Reviewers

Departments

Editorial

PhRMA 2008

David Nash, MD, MBA, discusses Pharmaceutical Industry Profile 2008, which documents the growth in spending and in product development by drug companies during the past two years.
David Nash, MD, MBA

Medication Errors

A Loud Wake-up Call: Unlabeled Containers Can Lead to Fatalities

Matthew Grissinger, RPh, FASCP, explains how hospital workers can prevent tragic outcomes by carefully labeling all medication containers and solutions.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

New Challenges to the FDA’s Drug-Labeling Policy

Stephen Barlas discusses new rules that might allow consumers to sue pharmaceutical companies in state courts over drug labeling.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Banzel to Vimpat, P&T presents the latest FDA approvals, new indications, recalls, and industry updates.

Drug Forecast

Tetrabenazine (Xenazine), An FDA-Approved Treatment Option for Huntington’s Disease–Related Chorea

Authors Yero and Rey review tetrabenazine (Xenazine) for Huntington’s chorea.
Tatiana Yero, PharmD, BS, and Jose A. Rey, PharmD, BCPP